Skip to main content
Erschienen in: World Journal of Surgery 8/2006

01.08.2006

Can Biliary Carcinoembryonic Antigen Identify Colorectal Cancer Patients with Occult Hepatic Metastases?

verfasst von: Giovanni Li Destri, MD, Raffaele Lanteri, MD, Marco Santangelo, MD, Benedetto Torrisi, MD, Antonio Di Cataldo, MD, Stefano Puleo, MD

Erschienen in: World Journal of Surgery | Ausgabe 8/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

Twenty-five percent of radically treated colorectal cancer patients already have occult hepatic metastases (OHM) that will later be observed during postoperative follow-up. Instrumental examinations, i.e., intraoperative ultrasound or Doppler perfusion index, have not improved diagnosis. As carcinoembyonic antigen (CEA) levels are useful to reveal hepatic metastases from colorectal cancer, determination of CEA in the bile rather than the blood may allow preclinical diagnosis of OHM thanks to the reduced volume of bile.

Methods

One hundred radically treated colorectal cancer patients were enrolled in the study. Bile was withdrawn from the gallbladder intraoperatively and biliary CEA levels determined using an immuno-enzymatic method (normal value 0–5 ng/ml). Eighty-nine fully evaluable patients were followed up for three years postoperatively to monitor hepatic metastases. Preoperative blood CEA, lymph node metastases and biliary CEA were compared in order to assess which procedure was more efficient in identifying patients who would develop hepatic metastases.

Results

Eleven of the 89 evaluable patients developed hepatic metastases: 9/11 presented elevated biliary CEA levels (mean: 12.73; range: 5.1–26.2); 8/11 had high preoperative blood CEA values; and 9/11 were at anatomopathological stage N+. In the 78 patients who did not develop hepatic metastases, biliary CEA was within normal limits in 73/78, preoperative blood CEA was normal in 60/78, and 58/78 patients were at anatomopathological stage N−. Hence, the sensitivity of biliary CEA was 81.8%, specificity was 93.6%, and diagnostic accuracy was 92.1%.

Conclusions

Determination of biliary CEA seems to be more efficient in identifying patients presenting OHM who require frequent clinical examinations or adjuvant cancer treatment.
Literatur
1.
Zurück zum Zitat Li Destri G, Craxi G, Rinzivillo C, et al. Il follow-up colorettale. Nostra esperienza. Chirurgia 1996;9:261–267 Li Destri G, Craxi G, Rinzivillo C, et al. Il follow-up colorettale. Nostra esperienza. Chirurgia 1996;9:261–267
2.
Zurück zum Zitat Finlay IG, McArdle CS. Occult hepatic metastases in colorectal carcinoma. Br J Surg 1986;73:732–735PubMed Finlay IG, McArdle CS. Occult hepatic metastases in colorectal carcinoma. Br J Surg 1986;73:732–735PubMed
3.
Zurück zum Zitat Adson MA. Resection of liver metastases: when is it worthwhile? World J Surg 1987;11:511–520PubMedCrossRef Adson MA. Resection of liver metastases: when is it worthwhile? World J Surg 1987;11:511–520PubMedCrossRef
4.
Zurück zum Zitat Fantini GA, De Cosse JJ. Surveillance strategies after resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1990;171:267–273PubMed Fantini GA, De Cosse JJ. Surveillance strategies after resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1990;171:267–273PubMed
5.
Zurück zum Zitat Finlay IG, Meek D, Brunton F, et al. Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg 1988;75:641–644PubMed Finlay IG, Meek D, Brunton F, et al. Growth rate of hepatic metastases in colorectal carcinoma. Br J Surg 1988;75:641–644PubMed
6.
Zurück zum Zitat Patel NA, Roh MS. Utility of intraoperative liver ultrasound. Surg Clin North Am 2004;84:513–524PubMedCrossRef Patel NA, Roh MS. Utility of intraoperative liver ultrasound. Surg Clin North Am 2004;84:513–524PubMedCrossRef
7.
Zurück zum Zitat Takeuchi N, Ramirez JN, Mortensen NJ, et al. Intraoperative ultrasonography in the diagnosis of hepatic metastases during surgery for colorectal cancer. Int J Colorectal Dis 1996;11:92–95PubMed Takeuchi N, Ramirez JN, Mortensen NJ, et al. Intraoperative ultrasonography in the diagnosis of hepatic metastases during surgery for colorectal cancer. Int J Colorectal Dis 1996;11:92–95PubMed
8.
Zurück zum Zitat Leen E, Angerson WJ, Wotherspoon H, et al. Comparison of the Doppler perfusion index and intraoperative ultrasonography in diagnosing colorectal liver metastases. Evaluation with postoperative follow-up results. Ann Surg 1994;220:663–667PubMed Leen E, Angerson WJ, Wotherspoon H, et al. Comparison of the Doppler perfusion index and intraoperative ultrasonography in diagnosing colorectal liver metastases. Evaluation with postoperative follow-up results. Ann Surg 1994;220:663–667PubMed
9.
Zurück zum Zitat Stone MD, Kane R, Bothe A, et al. Intraoperative ultrasound imaging of the liver at the time of colorectal cancer resection. Arch Surg 1994;129:431–435PubMed Stone MD, Kane R, Bothe A, et al. Intraoperative ultrasound imaging of the liver at the time of colorectal cancer resection. Arch Surg 1994;129:431–435PubMed
10.
Zurück zum Zitat Kopljar M, Brkljacic B, Doko M, et al. Nature of Doppler perfusion index changes in patients with colorectal cancer liver metastases. J Ultrasound Med 2004;23:1295–300PubMed Kopljar M, Brkljacic B, Doko M, et al. Nature of Doppler perfusion index changes in patients with colorectal cancer liver metastases. J Ultrasound Med 2004;23:1295–300PubMed
11.
Zurück zum Zitat Glover C, Douse P, Kane P, et al. Accuracy of investigations for asymptomatic colorectal liver metastases. Dis Colon Rectum 2002;45:476–484PubMedCrossRef Glover C, Douse P, Kane P, et al. Accuracy of investigations for asymptomatic colorectal liver metastases. Dis Colon Rectum 2002;45:476–484PubMedCrossRef
12.
Zurück zum Zitat Kruger S, Strobel D, Wehler M, et al. [Hepatic Doppler perfusion index—a sensitive screening method for detecting liver metastases?] Ultraschall Med 2000;21:206–209PubMedCrossRef Kruger S, Strobel D, Wehler M, et al. [Hepatic Doppler perfusion index—a sensitive screening method for detecting liver metastases?] Ultraschall Med 2000;21:206–209PubMedCrossRef
14.
Zurück zum Zitat Li Destri G, Greco S, Rinzivillo C, et al. Monitoring carcinoembryonic antigen in colorectal cancer: is it still useful? Surg Today 1998;28:1233–1236PubMedCrossRef Li Destri G, Greco S, Rinzivillo C, et al. Monitoring carcinoembryonic antigen in colorectal cancer: is it still useful? Surg Today 1998;28:1233–1236PubMedCrossRef
15.
Zurück zum Zitat Li Destri G, Rinzivillo C, Craxi G, et al. Colorectal follow-up planning modified on the basis of our personal experience. Dig Surg 1998;15:64–68PubMedCrossRef Li Destri G, Rinzivillo C, Craxi G, et al. Colorectal follow-up planning modified on the basis of our personal experience. Dig Surg 1998;15:64–68PubMedCrossRef
16.
Zurück zum Zitat Sugarbaker PH, Pianola FJ, Dwyer A, et al. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987;102:79–87PubMed Sugarbaker PH, Pianola FJ, Dwyer A, et al. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987;102:79–87PubMed
17.
Zurück zum Zitat Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994;219:174–182PubMed Bruinvels DJ, Stiggelbout AM, Kievit J, et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994;219:174–182PubMed
18.
Zurück zum Zitat Yeatman TJ, Rimura AK, Copeland EM, et al. Rapid analysis of carcinoembryonic antigen levels in gallbladder bile. Ann Surg 1991;213:113–117PubMed Yeatman TJ, Rimura AK, Copeland EM, et al. Rapid analysis of carcinoembryonic antigen levels in gallbladder bile. Ann Surg 1991;213:113–117PubMed
19.
Zurück zum Zitat Li Destri G, Curreri R, Lanteri R, et al. Biliary carcinoembryonic antigen in the diagnosis of occult hepatic metastases from colorectal cancer. J Surg Oncol 2002;81:8–11PubMedCrossRef Li Destri G, Curreri R, Lanteri R, et al. Biliary carcinoembryonic antigen in the diagnosis of occult hepatic metastases from colorectal cancer. J Surg Oncol 2002;81:8–11PubMedCrossRef
20.
Zurück zum Zitat Paul AA, Visser JJ, van Kamp GJ, et al. A simple extraction procedure for the determination of carcinoembryionic antigen in gallbladder bile. Ann Clin Biochem 1995;32:332–333PubMed Paul AA, Visser JJ, van Kamp GJ, et al. A simple extraction procedure for the determination of carcinoembryionic antigen in gallbladder bile. Ann Clin Biochem 1995;32:332–333PubMed
21.
Zurück zum Zitat Paul MA, Visser JJ, Mulder C, et al. Detection of occult liver metastases by measurement of biliary carcinoembryonic antigen concentrations. Eur J Surg 1996;162:483–488PubMed Paul MA, Visser JJ, Mulder C, et al. Detection of occult liver metastases by measurement of biliary carcinoembryonic antigen concentrations. Eur J Surg 1996;162:483–488PubMed
22.
Zurück zum Zitat Waisberg J, Palma RT, Neto LC, et al. Biliary carcinoembryonic antigen lavels in diagnosis of occult hepatic metastases from colorectal carcinoma. World J Gastroenterol 2003;9:1589–1593PubMed Waisberg J, Palma RT, Neto LC, et al. Biliary carcinoembryonic antigen lavels in diagnosis of occult hepatic metastases from colorectal carcinoma. World J Gastroenterol 2003;9:1589–1593PubMed
23.
Zurück zum Zitat Gennari L. Le metastasi epatiche. Chirurgia 1995;8:175–176 Gennari L. Le metastasi epatiche. Chirurgia 1995;8:175–176
24.
Zurück zum Zitat Taylor I. Liver metastases from colorectal cancer. Lessons from past and present clinical studies. Br J Surg 1996;83:456–460PubMed Taylor I. Liver metastases from colorectal cancer. Lessons from past and present clinical studies. Br J Surg 1996;83:456–460PubMed
25.
Zurück zum Zitat Wiratkapun S, Kraemer M, Seow-Choen F, et al. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum 2001;44:231–235PubMedCrossRef Wiratkapun S, Kraemer M, Seow-Choen F, et al. High preoperative serum carcinoembryonic antigen predicts metastatic recurrence in potentially curative colonic cancer: results of a five-year study. Dis Colon Rectum 2001;44:231–235PubMedCrossRef
26.
Zurück zum Zitat Wang WS, Lin JK, Chiou TJ, et al. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol 2000;30:12–16PubMedCrossRef Wang WS, Lin JK, Chiou TJ, et al. Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience. Jpn J Clin Oncol 2000;30:12–16PubMedCrossRef
27.
Zurück zum Zitat Allende T, Garcia Muniz JL, Vizoso F, et al. Preoperative serum levels of the carcinoembryonic antigen (CEA) and prognosis in colorectal cancer. Rev Esp Med Nucl 2001;20:358–364PubMed Allende T, Garcia Muniz JL, Vizoso F, et al. Preoperative serum levels of the carcinoembryonic antigen (CEA) and prognosis in colorectal cancer. Rev Esp Med Nucl 2001;20:358–364PubMed
28.
Zurück zum Zitat Ishizuka D, ShiraiY, Sakai Y, et al. Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19–9 levels. Int J Colorectal Dis 2001;16:32–37PubMedCrossRef Ishizuka D, ShiraiY, Sakai Y, et al. Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19–9 levels. Int J Colorectal Dis 2001;16:32–37PubMedCrossRef
29.
Zurück zum Zitat Marquena J, Acosta MA, Garcia-Anguiano F, et al. Use of the preoperative levels of CEA in patients with colorectal cancer. Hepatogastroenterology 2003;50:1017–1020 Marquena J, Acosta MA, Garcia-Anguiano F, et al. Use of the preoperative levels of CEA in patients with colorectal cancer. Hepatogastroenterology 2003;50:1017–1020
30.
Zurück zum Zitat Braat AE, Oosterhuis JWA, Moll FCP, et al. Successful sentinel node identification in colon carcinoma using Patent Blue V. Eur J Surg Oncol 2004;30:633–637PubMedCrossRef Braat AE, Oosterhuis JWA, Moll FCP, et al. Successful sentinel node identification in colon carcinoma using Patent Blue V. Eur J Surg Oncol 2004;30:633–637PubMedCrossRef
31.
Zurück zum Zitat Yuan HY, Cheng FL, Wei ZZ, et al. Clinical significance of detecting lymph node micrometastasis of colorectal cancer by reverse transcriptase-polymerase chain reaction (RT-PCR)] Ai Zheng. 2004;23:1069–1073PubMed Yuan HY, Cheng FL, Wei ZZ, et al. Clinical significance of detecting lymph node micrometastasis of colorectal cancer by reverse transcriptase-polymerase chain reaction (RT-PCR)] Ai Zheng. 2004;23:1069–1073PubMed
32.
Zurück zum Zitat Mukai M, Sato S, Komatsu M, et al. Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with curatively resected Dukes’ B colorectal cancer. Oncol Rep 2003;10:1177–1181PubMed Mukai M, Sato S, Komatsu M, et al. Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with curatively resected Dukes’ B colorectal cancer. Oncol Rep 2003;10:1177–1181PubMed
33.
Zurück zum Zitat Li Destri G, Gravagna G, Zappalà O, et al. Linfoadenectomia “en bloc” per cancro colorettale: numero di linfonodi e ratio come fattori prognostici. Tumori 2005;4(suppl):18–20 Li Destri G, Gravagna G, Zappalà O, et al. Linfoadenectomia “en bloc” per cancro colorettale: numero di linfonodi e ratio come fattori prognostici. Tumori 2005;4(suppl):18–20
34.
Zurück zum Zitat Paganuzzi M, Onetto M, De Paoli M, et al. Carcinoembryonic antigen (CEA) in serum and bile of colorectal cancer patients with or without detectable liver metastases. Anticancer Res 1994;14:1409–1412PubMed Paganuzzi M, Onetto M, De Paoli M, et al. Carcinoembryonic antigen (CEA) in serum and bile of colorectal cancer patients with or without detectable liver metastases. Anticancer Res 1994;14:1409–1412PubMed
35.
Zurück zum Zitat Kutun S, Celik A, Hatoboglu C, et al. Carcinoembryonic antigen to detect hepatic metatases of colorectal cancers. Surg Today 2003;33:590–594PubMedCrossRef Kutun S, Celik A, Hatoboglu C, et al. Carcinoembryonic antigen to detect hepatic metatases of colorectal cancers. Surg Today 2003;33:590–594PubMedCrossRef
36.
Zurück zum Zitat Dorrance HR, McGregor JR, McAllister RJ, et al. Bile carcinoembryonic antigen levels and occult hepatic metastases from colorectal cancer. Dis Colon Rectum 2000;43:1292–1295PubMedCrossRef Dorrance HR, McGregor JR, McAllister RJ, et al. Bile carcinoembryonic antigen levels and occult hepatic metastases from colorectal cancer. Dis Colon Rectum 2000;43:1292–1295PubMedCrossRef
37.
Zurück zum Zitat Frikart L, Fournier K, Mach JP, et al. Potential value of biliary CEA assay in early detection of colorectal adenocarcinoma liver metatases. Eur J Surg Oncol 1995;21:276–279PubMedCrossRef Frikart L, Fournier K, Mach JP, et al. Potential value of biliary CEA assay in early detection of colorectal adenocarcinoma liver metatases. Eur J Surg Oncol 1995;21:276–279PubMedCrossRef
38.
Zurück zum Zitat Ishida H, Yoshinaga K, Gonda T, et al. Biliary carcinoembrionic antigen levels can predict metachronous liver metastasis of colorectal cancer. Anticancer Res 2000;20:523–526PubMed Ishida H, Yoshinaga K, Gonda T, et al. Biliary carcinoembrionic antigen levels can predict metachronous liver metastasis of colorectal cancer. Anticancer Res 2000;20:523–526PubMed
39.
Zurück zum Zitat Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997;89:497–505CrossRef Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997;89:497–505CrossRef
40.
Zurück zum Zitat Beart RW, Moertel CG, Wieand HS, et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 1990;125:897–901PubMed Beart RW, Moertel CG, Wieand HS, et al. Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 1990;125:897–901PubMed
41.
Zurück zum Zitat Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990;8:1466–1475PubMed Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990;8:1466–1475PubMed
42.
Zurück zum Zitat Nitti D, Wils J, Sahmoud T, et al. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983–1987). European Organisation for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer 1997;33:1209–1215PubMedCrossRef Nitti D, Wils J, Sahmoud T, et al. Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983–1987). European Organisation for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer 1997;33:1209–1215PubMedCrossRef
43.
Zurück zum Zitat Rougier P, Sahmoud T, Nitti D, et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research. Lancet 1998;351:1677–1681PubMedCrossRef Rougier P, Sahmoud T, Nitti D, et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research. Lancet 1998;351:1677–1681PubMedCrossRef
44.
Zurück zum Zitat Focan C, Bury J, Beauduin M, et al. Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Regional d’Etude du Cancer Colo-Rectal (Belgium). Anticancer Drugs 2000;11:549–554PubMedCrossRef Focan C, Bury J, Beauduin M, et al. Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Regional d’Etude du Cancer Colo-Rectal (Belgium). Anticancer Drugs 2000;11:549–554PubMedCrossRef
45.
Zurück zum Zitat Fielding LP, Hittinger R, Grace RH, et al. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502–506PubMedCrossRef Fielding LP, Hittinger R, Grace RH, et al. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992;340:502–506PubMedCrossRef
46.
Zurück zum Zitat Metzger U, Laffer U, Egeli R, et al. Status of portal perfusion in colorectal cancer. Swiss Study Group for Clinical Cancer Research. Chirurg 1994;65:509–513PubMed Metzger U, Laffer U, Egeli R, et al. Status of portal perfusion in colorectal cancer. Swiss Study Group for Clinical Cancer Research. Chirurg 1994;65:509–513PubMed
47.
Zurück zum Zitat Yamamura T, Yabe K, Oka H, et al. Intraportal Chemotherapy for Colorectal Cancer Group. [Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group.] Gan To Kagaku Ryoho 2002;29:1765–1771PubMed Yamamura T, Yabe K, Oka H, et al. Intraportal Chemotherapy for Colorectal Cancer Group. [Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group.] Gan To Kagaku Ryoho 2002;29:1765–1771PubMed
Metadaten
Titel
Can Biliary Carcinoembryonic Antigen Identify Colorectal Cancer Patients with Occult Hepatic Metastases?
verfasst von
Giovanni Li Destri, MD
Raffaele Lanteri, MD
Marco Santangelo, MD
Benedetto Torrisi, MD
Antonio Di Cataldo, MD
Stefano Puleo, MD
Publikationsdatum
01.08.2006
Erschienen in
World Journal of Surgery / Ausgabe 8/2006
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-005-0698-1

Weitere Artikel der Ausgabe 8/2006

World Journal of Surgery 8/2006 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.